Viridian Therapeutics
6200 Lookout Road
Suite 100
Boulder
Colorado
80301
United States
Tel: 720-643-5200
Fax: 720-643-5201
204 articles about Viridian Therapeutics
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2024
4/4/2024
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to three new employees on April 1, 2024.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 06, 2024
3/6/2024
Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 62,000 shares of the company’s common stock to two new employees on March 1, 2024.
-
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
3/5/2024
Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
-
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
2/27/2024
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
-
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
2/16/2024
Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer.
-
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 06, 2024
2/6/2024
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 30,000 shares of the company’s common stock on February 1, 2024.
-
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
1/18/2024
Viridian Therapeutics, Inc. announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million.
-
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
1/8/2024
Viridian Therapeutics, Inc. today announced that President and Chief Executive Officer, Steve Mahoney, will discuss the company’s progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
-
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
Viridian Therapeutics, Inc. today announced that its President and Chief Executive Officer, Steve Mahoney, will present an overview of the company along with its upcoming corporate priorities at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 7:30am PT / 10:30am ET in San Francisco.
-
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
12/18/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the selection of VRDN-003 as its lead subcutaneous (SC) program for thyroid eye disease (TED) based on positive data from a Phase 1 clinical study in healthy volunteers.
-
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
11/21/2023
Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, November 30 at 11:15am ET in Miami, Florida.
-
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.
-
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
11/8/2023
Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 4:00 p.m. GMT in London, UK.
-
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
11/3/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that multiple abstracts featuring clinical and preclinical data on the company’s pipeline candidates for the treatment of thyroid eye disease (TED) will be presented at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO 2023), to be held November 3-6, 2023, in San Francisco, California.
-
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
10/30/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that Stephen Mahoney has been appointed the company’s President and Chief Executive Officer, and a member of the Board of Directors, effective immediately.
-
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
10/26/2023
Viridian Therapeutics, Inc. and Ypsomed AG (SIX: YPSN), the leading developer and manufacturer of injection and infusion systems for self-medication have signed a supply agreement for Ypsomed’s customizable YpsoMate 2.25 autoinjector pen device with a fill volume of 2.0 milliliters.
-
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
9/25/2023
Viridian Therapeutics, Inc. today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.
-
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September 2023
9/7/2023
Viridian Therapeutics, Inc. announced that multiple abstracts featuring clinical and preclinical data on the Company’s pipeline candidates for the treatment of thyroid eye disease will be presented at the following medical meetings.
-
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the second quarter ended June 30, 2023.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - August 04, 2023
8/4/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to two new employees on August 1, 2023.